Clinical Trial Update: Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study [Phase 3]

View source ↗

Summary

A Phase 3, placebo-controlled, double-blind multicenter trial evaluating tacrolimus (FK506) for lupus nephritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Tacrolimus (Tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Lupus Nephritis | Phase 3 | Status: COMPLETED